Literature DB >> 21774590

High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.

Alan M Kwong1, Brigette L Tippin, Alicia M Materi, Virgilio S Buslon, Samuel W French, Henry J Lin.   

Abstract

High doses of niacin (nicotinic acid) used to treat dyslipidemias cause flushing, due to high levels of prostaglandin D(2) (PGD(2)). GPR109A, a G-protein coupled receptor, triggers the flushing in the skin. In addition to boosting PGD(2), niacin binding to GPR109A activates the entire prostanoid cascade. We found that GPR109A occurs throughout the gastrointestinal tract. Mice that alternated between a 1% niacin diet and a control diet had higher urinary prostaglandin E(2) (PGE(2)) metabolite levels when on niacin (2.8-fold increase; 95% confidence interval, 1.8-3.9). PGE(2) promotes tumors in the intestines, whereas PGD(2) may have an opposite effect, on the basis of our report showing that transgenic hematopoietic prostaglandin D synthase suppresses intestinal adenomas in Apc(Min/+) mice. To determine if either tumor growth or tumor suppression prevails, we fed Apc(Min/+) mice a 1% niacin diet and assessed tumor development. A 1% niacin diet did not affect the number of tumors scored histologically in Apc(Min/+) mice at 14 wk (33 mice on niacin, 33 controls). Although niacin stimulates production of various prostaglandins, our results support an interpretation that very high intakes of niacin are safe in relation to intestinal tumors in this model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21774590      PMCID: PMC3224853          DOI: 10.1080/01635581.2011.590266

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  35 in total

1.  The influence of nutritional factors on pulmonary adenomas in mice.

Authors:  F A French
Journal:  Adv Exp Med Biol       Date:  1977       Impact factor: 2.622

2.  Tolerance to nicotinic acid flushing.

Authors:  R H Stern; J D Spence; D J Freeman; A Parbtani
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

3.  Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice.

Authors:  B Toth
Journal:  Oncology       Date:  1983       Impact factor: 2.935

4.  The "Swiss roll": a simple technique for histological studies of the rodent intestine.

Authors:  C Moolenbeek; E J Ruitenberg
Journal:  Lab Anim       Date:  1981-01       Impact factor: 2.471

5.  Modification of renal tumorigenic effect of streptozotocin by nicotinamide: spontaneous reversibility of streptozotocin diabetes.

Authors:  N Rakieten; B S Gordon; A Beaty; D A Cooney; P S Schein; R L Dixon
Journal:  Proc Soc Exp Biol Med       Date:  1976-02

6.  Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.

Authors:  J D Morrow; W G Parsons; L J Roberts
Journal:  Prostaglandins       Date:  1989-08

7.  Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.

Authors:  Julien Hanson; Andreas Gille; Sabrina Zwykiel; Martina Lukasova; Björn E Clausen; Kashan Ahmed; Sorin Tunaru; Angela Wirth; Stefan Offermanns
Journal:  J Clin Invest       Date:  2010-07-26       Impact factor: 14.808

8.  G protein-coupled receptor for nicotinic acid in mouse macrophages.

Authors:  Anna Lorenzen; Christina Stannek; Anja Burmeister; Ivars Kalvinsh; Ulrich Schwabe
Journal:  Biochem Pharmacol       Date:  2002-08-15       Impact factor: 5.858

9.  Promoting effect of nicotinamide on the development of renal tubular cell tumors in rats initiated with diethylnitrosamine.

Authors:  M R Rosenberg; D L Novicki; R L Jirtle; A Novotny; G Michalopoulos
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

10.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.

Authors:  Sorin Tunaru; Jukka Kero; Annette Schaub; Christian Wufka; Andree Blaukat; Klaus Pfeffer; Stefan Offermanns
Journal:  Nat Med       Date:  2003-02-03       Impact factor: 53.440

View more
  1 in total

1.  Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR.

Authors:  Brigette L Tippin; Alan M Kwong; Michael J Inadomi; Oliver J Lee; Jae Man Park; Alicia M Materi; Virgilio S Buslon; Amy M Lin; Lili C Kudo; Stanislav L Karsten; Samuel W French; Shuh Narumiya; Yoshihiro Urade; Eduardo Salido; Henry J Lin
Journal:  Cancer Med       Date:  2014-04-12       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.